Clinical Trial Update: BMN 110 US Expanded Access Program

View source ↗

Summary

Expanded access program update for BMN 110 (elosulfase alfa) in Morquio A Syndrome (MPS IVA); status indicates marketing approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Morquio Syndrome
• Mps Iva
• Mucopolysaccharidosis Iva

Drugs mentioned

• BMN 110 (elosulfase alfa) (elosulfase alfa)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Mucopolysaccharidosis IVA, Morquio A Syndrome | Status: APPROVED_FOR_MARKETING